145 related articles for article (PubMed ID: 29727321)
1. Fluorescent In Situ Hybridization in Surgical Pathology Practice.
Gupta R; Cooper WA; Selinger C; Mahar A; Anderson L; Buckland ME; O'Toole SA
Adv Anat Pathol; 2018 Jul; 25(4):223-237. PubMed ID: 29727321
[TBL] [Abstract][Full Text] [Related]
2. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
3. The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays.
Babic A; Loftin IR; Stanislaw S; Wang M; Miller R; Warren SM; Zhang W; Lau A; Miller M; Wu P; Padilla M; Grogan TM; Pestic-Dragovich L; McElhinny AS
Methods; 2010 Dec; 52(4):287-300. PubMed ID: 20807574
[TBL] [Abstract][Full Text] [Related]
4. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
5. A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay.
Bartlett JM; Campbell FM; Ibrahim M; O'Grady A; Kay E; Faulkes C; Collins N; Starczynski J; Morgan JM; Jasani B; Miller K
Am J Clin Pathol; 2011 Jan; 135(1):157-62. PubMed ID: 21173138
[TBL] [Abstract][Full Text] [Related]
6. Pathology-based Biomarkers Useful for Clinical Decisions in Melanoma.
Torres-Cabala C; Li-Ning-Tapia E; Hwu WJ
Arch Med Res; 2020 Nov; 51(8):827-838. PubMed ID: 32950263
[TBL] [Abstract][Full Text] [Related]
7. Updated UK Recommendations for HER2 assessment in breast cancer.
Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR.
Koudelakova V; Berkovcova J; Trojanec R; Vrbkova J; Radova L; Ehrmann J; Kolar Z; Melichar B; Hajduch M
J Mol Diagn; 2015 Jul; 17(4):446-55. PubMed ID: 25956448
[TBL] [Abstract][Full Text] [Related]
9. Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry.
Helin HO; Tuominen VJ; Ylinen O; Helin HJ; Isola J
Virchows Arch; 2016 Feb; 468(2):191-8. PubMed ID: 26493985
[TBL] [Abstract][Full Text] [Related]
10. Fluorescent in situ hybridization and array comparative genomic hybridization: complementary techniques for genomic evaluation.
Morrison C
Arch Pathol Lab Med; 2006 Jul; 130(7):967-74. PubMed ID: 16831052
[TBL] [Abstract][Full Text] [Related]
11. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
12. Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting.
Green IF; Zynger DL
Hum Pathol; 2015 Dec; 46(12):1842-9. PubMed ID: 26412217
[TBL] [Abstract][Full Text] [Related]
13. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
Press MF; Sauter G; Buyse M; Fourmanoir H; Quinaux E; Tsao-Wei DD; Eiermann W; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Mackey JR; Bee V; Ma Y; Villalobos I; Campeau A; Mirlacher M; Lindsay MA; Slamon DJ
J Clin Oncol; 2016 Oct; 34(29):3518-3528. PubMed ID: 27573653
[TBL] [Abstract][Full Text] [Related]
14. Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practice.
Farshid G; Armes JE; Bell R; Cummings M; Fox S; Francis G; Haswell M; Morey A; McCue G; Raymond W; Robbins P; Bilous M
Diagn Mol Pathol; 2010 Dec; 19(4):187-93. PubMed ID: 21052003
[TBL] [Abstract][Full Text] [Related]
15. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.
Dietel M; Ellis IO; Höfler H; Kreipe H; Moch H; Dankof A; Kölble K; Kristiansen G
Virchows Arch; 2007 Jul; 451(1):19-25. PubMed ID: 17562074
[TBL] [Abstract][Full Text] [Related]
16. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.
Carbone A; Botti G; Gloghini A; Simone G; Truini M; Curcio MP; Gasparini P; Mangia A; Perin T; Salvi S; Testi A; Verderio P
J Mol Diagn; 2008 Nov; 10(6):527-36. PubMed ID: 18832456
[TBL] [Abstract][Full Text] [Related]
17. The FlexISH assay brings flexibility to cytogenetic HER2 testing.
Brockhoff G; Bock M; Zeman F; Hauke S
Histopathology; 2016 Oct; 69(4):635-46. PubMed ID: 27008983
[TBL] [Abstract][Full Text] [Related]
18. HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH.
Grin A; Brezden-Masley C; Bauer S; Streutker CJ
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):561-6. PubMed ID: 23455182
[TBL] [Abstract][Full Text] [Related]
19. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.
Hanna WM; Barnes PJ; Chang MC; Gilks CB; Magliocco AM; Rees H; Quenneville L; Robertson SJ; SenGupta SK; Nofech-Mozes S
J Clin Oncol; 2014 Dec; 32(35):3967-73. PubMed ID: 25385731
[TBL] [Abstract][Full Text] [Related]
20. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
